| 1P5Z |
1.6 |
Structure of human dCK complexed with cytarabine and ADP-MG |
| 1P60 |
1.96 |
Structure of human dCK complexed with 2'-Deoxycytidine and ADP, Space group C 2 2 21 |
| 1P61 |
2.21 |
Structure of human dCK complexed with 2'-Deoxycytidine and ADP, P 43 21 2 space group |
| 1P62 |
1.9 |
Structure of human dCK complexed with gemcitabine and ADP-MG |
| 2A2Z |
3.02 |
Crystal Structure of human deoxycytidine kinase in complex with deoxycytidine and uridine diphosphate |
| 2A30 |
3.02 |
Crystal structure of human deoxycytidine kinase in complex with deoxycytidine |
| 2A7Q |
2.55 |
Crystal structure of human dCK complexed with clofarabine and ADP |
| 2NO0 |
1.8 |
C4S dCK variant of dCK in complex with gemcitabine+ADP |
| 2NO1 |
1.91 |
C4S dCK variant of dCK in complex with D-dC+ADP |
| 2NO6 |
1.9 |
C4S dCK variant of dCK in complex with FTC+ADP |
| 2NO7 |
1.7 |
C4S dCK variant of dCK in complex with L-dC+ADP |
| 2NO9 |
2.15 |
The structure of deoxycytidine kinase complexed with troxacitabine and ADP. |
| 2NOA |
1.8 |
The structure of deoxycytidine kinase complexed with lamivudine and ADP. |
| 2QRN |
3.4 |
Human Deoxycytidine kinase dCMP, UDP, Mg ion product complex |
| 2QRO |
3.45 |
Human Deoxycytidine kinase dAMP, UDP, Mg ion product complex |
| 2ZI3 |
2.3 |
C4S-E247A dCK variant of dCK in complex with D-dA+ADP |
| 2ZI4 |
2.1 |
C4S dCK variant of dCK in complex with L-dA+ADP |
| 2ZI5 |
1.77 |
C4S dCK variant of dCK in complex with L-dA+UDP |
| 2ZI6 |
1.77 |
C4S dCK variant of dCK in complex with D-dA+UDP |
| 2ZI7 |
1.97 |
C4S dCK variant of dCK in complex with D-dG+UDP |
| 2ZI9 |
2.51 |
C4S-E247A dCK variant of dCK in complex with cladribine+ADP |
| 2ZIA |
1.8 |
C4S dCK variant of dCK in complex with cladribine+UDP |
| 3HP1 |
2.31 |
Crystal structure of human dCK R104M/D133A in complex with L-dT and ADP |
| 3IPX |
2.0 |
X-Ray structure of Human Deoxycytidine Kinase in complex with ADP and an inhibitor |
| 3IPY |
2.54 |
X-Ray structure of Human Deoxycytidine Kinase in complex with an inhibitor |
| 3KFX |
1.96 |
Human dCK complex with 5-Me dC and ADP |
| 3MJR |
2.1 |
Human dCK complex with Acyclic Nucleoside |
| 3QEJ |
2.49 |
S74E-dCK mutant in complex with UDP |
| 3QEN |
1.997 |
S74E dCK in complex with 5-bromodeoxycytidine and UDP |
| 3QEO |
1.897 |
S74E-R104M-D133A dCK variant in complex with L-deoxythymidine and UDP |
| 4JLJ |
2.0 |
Human dCK C4S-S74E mutant in complex with UDP and the F2.1.1 inhibitor (2-[({2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE) |
| 4JLK |
1.89 |
Human dCK C4S-S74E mutant in complex with UDP and the F2.2.1 inhibitoR (2-[({2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-5-METHYL-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE) |
| 4JLM |
2.18 |
Human dCK C4S-S74E mutant in complex with UDP and the F2.3.1 inhibitor (2-[({5-ETHYL-2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE) |
| 4JLN |
2.15 |
Human dCK C4S-S74E mutant in complex with UDP and the F2.4.1 inhibitor (2-[({2-[3-(2-FLUOROETHOXY)-4-METHOXYPHENYL]-5-PROPYL-1,3-THIAZOL-4-YL}METHYL)SULFANYL]PYRIMIDINE-4,6-DIAMINE) |
| 4KCG |
2.09 |
Human dCK C4S-S74E mutant in complex with UDP and the DI-39 inhibitor |
| 4L5B |
1.94 |
Human dCK C4S-S74E mutant in complex with UDP and the DI-43 inhibitor |
| 4Q18 |
2.0 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 4 [1-[5-(4-{[(2,6-diaminopyrimidin-4-yl)sulfanyl]methyl}-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]-2-methylpropan-2-ol] |
| 4Q19 |
2.09 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 5 {5-(4-{[(4,6-DIAMINOPYRIMIDIN-2-YL)SULFANYL]METHYL}-5-PROPYL-1,3-THIAZOL-2-YL)-2-METHOXYPHENOL} |
| 4Q1A |
1.9 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 6 {2-[5-(4-{[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl}-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethanol} |
| 4Q1B |
2.15 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 7 {N-(2-(3-(4-(((4,6-diaminopyrimidin-2-yl)thio)methyl)-5-propylthiazol-2-yl)phenoxy)ethyl)methanesulfonamide} |
| 4Q1C |
2.0 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 8 {2,2'-[{4-[(2R)-4-{[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl}-5-propyl-2,3-dihydro-1,3-thiazol-2-yl]benzene-1,2-diyl}bis(oxy)]diethanol} |
| 4Q1D |
2.0 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 9 {2-{[(1R)-1-{2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-propyl-1,3-thiazol-4-yl}ethyl]sulfanyl}pyrimidine-4,6-diamine} |
| 4Q1E |
1.85 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 10 {2-{[(1R/S)-1-{2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-methyl-1,3-thiazol 4-yl}ethyl]sulfanyl}pyrimidine-4,6-diamine} |
| 4Q1F |
2.1 |
Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 12R {N-{2-[5-(4-{(1R)-1-[(4,6-diaminopyrimidin-2-yl)sulfanyl]ethyl}-5-methyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethyl}methanesulfonamide} |
| 5MQJ |
3.7 |
Crystal structure of dCK mutant C3S |
| 5MQL |
3.25 |
Crystal structure of dCK mutant C3S in complex with masitinib and UDP |
| 5MQT |
3.2 |
Crystal structure of dCK mutant C3S in complex with imatinib and UDP |
